(Q43890930)

English

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

scientific article published on 13 March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 November 2017

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research (English)

1 reference

Europe PubMed Central

27 November 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

malaria vaccine

1 reference

based on heuristic

inferred from title

W Ripley Ballou

18

object named as

W Ripley Ballou

1 reference

Europe PubMed Central

27 November 2017

Christian F Ockenhouse

3

object named as

Christian F Ockenhouse

1 reference

Europe PubMed Central

27 November 2017

D. Gray Heppner

20

object named as

D Gray Heppner

1 reference

Europe PubMed Central

27 November 2017

author name string

Kent E Kester

1

1 reference

Europe PubMed Central

27 November 2017

James F Cummings

2

1 reference

Europe PubMed Central

27 November 2017

Robin Nielsen

4

1 reference

Europe PubMed Central

27 November 2017

B Ted Hall

5

1 reference

Europe PubMed Central

27 November 2017

Daniel M Gordon

6

1 reference

Europe PubMed Central

27 November 2017

Robert J Schwenk

7

1 reference

Europe PubMed Central

27 November 2017

Urszula Krzych

8

1 reference

Europe PubMed Central

27 November 2017

Carolyn A Holland

9

1 reference

Europe PubMed Central

27 November 2017

Gregory Richmond

10

1 reference

Europe PubMed Central

27 November 2017

Megan G Dowler

11

1 reference

Europe PubMed Central

27 November 2017

Jackie Williams

12

1 reference

Europe PubMed Central

27 November 2017

Robert A Wirtz

13

1 reference

Europe PubMed Central

27 November 2017

Nadia Tornieporth

14

1 reference

Europe PubMed Central

27 November 2017

Laurence Vigneron

15

1 reference

Europe PubMed Central

27 November 2017

Martine Delchambre

16

1 reference

Europe PubMed Central

27 November 2017

Marie-Ange Demoitie

17

1 reference

Europe PubMed Central

27 November 2017

Joe Cohen

19

1 reference

Europe PubMed Central

27 November 2017

RTS,S Malaria Vaccine Evaluation Group

21

1 reference

Europe PubMed Central

27 November 2017

language of work or name

0 references

publication date

13 March 2008

1 reference

Europe PubMed Central

27 November 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

27 November 2017

26

1 reference

Europe PubMed Central

27 November 2017

2191-2202

1 reference

Europe PubMed Central

27 November 2017

18

1 reference

Europe PubMed Central

27 November 2017

The global distribution of clinical episodes of Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

The uncertain burden of Plasmodium falciparum epidemics in Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Controversies and misconceptions in malaria chemoprophylaxis for travelers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Conquering the intolerable burden of malaria: what's new, what's needed: a summary.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Reducing the burden of malaria in different eco-epidemiological settings with environmental management: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Insecticide-treated bed nets and curtains for preventing malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Epidemiology of drug-resistant malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Current issues for anti-malarial drugs to control P. falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Vaccines against malaria - an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Assay, purification and characterization of a recombinant malaria circumsporozoite fusion protein by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Malaria transmitted to humans by mosquitoes infected from cultured plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Functional signatures of protective antiviral T-cell immunity in human virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.048

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.02.048

1 reference

Europe PubMed Central

27 November 2017

1 reference

Europe PubMed Central

27 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43890930&oldid=2104183595"